AzTrials
AzTrials

Functional Neurological DisorderNCT06084325

The Role of Oxytocin and Interoception in Functional Neurological Disorder

An observational study of Functional Neurological Disorder, run by University of Fribourg at 2 sites in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main goal of this project is to better understand the role of oxytocin and Interoception in FND. More specifically oxytocin's association with precision weighing, prediction errors and priors in the interoceptive domains will be investigated. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Functional Neurological Disorder
What is being tested?
Respiration resistance sensitivity task (RRST), Heartbeat Tracking (HBT) and Heartbeat evoked potential (HEP)
How many people
110 participants
Where
2 sitesSwitzerland
Study dates
5 Oct 2023to 24 Jan 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: FND patients Participants who are patients will be recruited from the in- and out-patients pool of the Clinic for Neurology of the Hospital of Fribourg and the Inselspital. At both, the treating physician will identify suitable patients (i.e. patients who fulfil the clinical requirement for FND as described in the DSM-5). The treating physician will ask these patients whether they would like to be approached by the Investigator (or his/her designee) concerning a scientific study. In case of affirmative response, the Investigator will approach the patients, inform them about the study. Healthy control Healthy controls will be recruited among students, collaborators, and visitors of the University of Fribourg and Bern, the Hospital of Fribourg and the Inselspital. They will be recruited by flyer, by word-of-mouth and through advertisements in public media.

Who may be able to join

  • A diagnosis of FND according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria
  • Capable of judgement
  • Willing to participate in the study (by signing the informed consent form)
  • Capable of judgement
  • Willing to participate in the study (by signing the informed consent form)

Who cannot join

  • Presence of comorbid disorders such as psychosis or major depression with suicidal risk
  • History of actual or suspected epilepsy
  • Past surgery in the brain
  • Cardio-vascular disease
  • Implanted Investigational Medicinal Products (e.g. cochlear implants, neurostimulators, cardiac pacemakers)
  • History of alcohol or drug abuse
Show all 19Show fewer
  • For female participants: breastfeeding, pregnancy (a standard urine pregnancy test will be provided)
  • <6h prior application prostaglandin
  • Long QT-syndrome
  • Inability to follow the procedures of the study, e.g. due to language problems
  • History of actual or suspected epilepsy
  • Past surgery in the brain
  • Cardio-vascular disease
  • Implanted Investigational Medicinal Products (e.g. cochlear implants, neurostimulators, cardiac pacemakers)
  • History of alcohol or drug abuse
  • For female participants: breastfeeding, pregnancy (a standard urine pregnancy test will be provided)
  • <6h prior application prostaglandin
  • Long QT-syndrome
  • Inability to follow the procedures of the study, e.g. due to language problems

Trial locations and contacts

2 sites in 1 country.

Switzerland2 sites
  • Inselspital

    Bern, Canton of Bern, 3010

  • University of Fribourg

    Fribourg, Canton of Fribourg, 1700

Other trials in Switzerland

About this study

The main goal of this project is to better understand the role of oxytocin and Interoception in FND. More specifically oxytocin's association with precision weighing, prediction errors and priors in the interoceptive domains will be investigated. To this end, several methods will be employed: analysis of interoceptive accuracy and sensibility (interoceptive tasks and questionnaires), biomarkers of oxytocin (peripheral, endogenous oxytocin), genetic oxytocin markers (such as allele-frequency in the oxytonergic receptor gene), epigenetics (methylation rates of genes related to oxytocin), neuroactivity (EEG).

Read the detailed description

The primary objective is to explore interoceptive processing during a behavioural (interoceptive) tasks and its association to the oxytocin (OT) system in patients affected by a functional neurological disorder (FND), in comparison to healthy controls (HC).

Concerning interoception, as primary outcome, it is hypothesized that:

  1. FND patients are less interoceptive (judged by objectively measured accuracy) compared to HC in the interoceptive tasks.

Concerning OT, as primary outcome, it is hypothesized that:

  1. The OT level is correlated with interoception tasks; specifically the adaption of precision weighting

The secondary objectives are to:

  • Explore the validity and reliability of different interoceptive tasks (e.g. respiratory, cardiovascular, emotional tasks)
  • Explore neuronal regions associated with interoceptive processing and interoceptive accuracy in FND compared to HC
  • Investigate whether FND patients have a higher interoception trait-prediction error (discrepancy between subjective and objective interoception scores) and whether this correlates with their symptom severity
  • Explore the association of the breathing cycle and the voluntary initiation of mental or motor actions, and its readiness potential
  • Explore peripheral biomarkers (e.g. salivary OT) in FND patients, compared to HC
  • Explore the differences in (epi)genetic profile associated with the OT-system in FND compared to HC
  • Investigate the association of the OT-system and traumatic childhood experience, attachment styles and sexual functioning in patients of FND compared to HC
Being tested
Respiration resistance sensitivity task (RRST), Heartbeat Tracking (HBT), Heartbeat evoked potential (HEP), Libet task
Medical subject headings
Conversion Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Respiration resistance sensitivity task (RRST)Device

    Also called Respiration resistance device

    The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.

  • Heartbeat Tracking (HBT)Behavioural

    Also called ECG

    The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).

  • Heartbeat evoked potential (HEP)Device

    Also called ECG + EEG

    The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.

  • Libet taskDevice

    Also called Respiration belt + EEG

    Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.

Study groups in NCT06084325
Study groupRoleWhat they receive
FND PatientsGroup of patients with functional neurological disorders
Receives: Device: Respiration resistance sensitivity task (RRST); Behavioral: Heartbeat Tracking (HBT); Device: Heartbeat evoked potential (HEP); Device: Libet task
Healthy controlAge matched group control of healthy participant
Receives: Device: Respiration resistance sensitivity task (RRST); Behavioral: Heartbeat Tracking (HBT); Device: Heartbeat evoked potential (HEP); Device: Libet task

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference of interoception behavioural scores between FND patients and Healthy controls

    Assessment of the difference between interoception tasks scores between these groups. These scores evaluated the interoception processing abilities of patient/control.

    Measured: 1 day

  2. Difference in brain electrophysiology during interoception processing between FND patients and Healthy controls

    Assessment of the difference Evoked Related potential (ERPs) during interoception taks between these groups.

    Measured: 1 day

  3. Association between oxytocin system and interoception and its difference between FND patients and Healthy controls

    Study of the correlation between oxytocin system and interoception indices. Oxytocin system was studied with oxytocin concentration (saliva) and genetic markers (blood analysis).

    Measured: 1 day

Secondary outcomes (10)
  1. Oxytocin concentration (Saliva sampling)

    During the day of the experimental session, 4 samples of saliva at different time are collected. These sample will be used to determine the concentration of oxytocin during the day (30 min post awakening, 30min after lunch, at tasks, upon the arrival for experimental session, after the completion of all tasks).

    Measured: 1 day

  2. Epigenetic profile

    Blood sample are used for genetic analysis on the oxytocin markers (such as allele-frequency in the oxytonergic receptor gene). Correlation of this with interoceptive scores.

    Measured: 1 day

  3. Respiratory Resistance Sensitivity

    Difference of accuracy between FND patients and healthy control in the respiratory resistance sensitivity task.

    Measured: 1 day

  4. Behavioral measure: heartbeat counting

    Difference of accuracy between FND patients and healthy control to count the number of their own heartbeats.

    Measured: 1 day

  5. Electrophysiological measure (EEG): Heartbeat evoked potential (HEP) task1

    First, study the HEP difference between interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). Then comparison between FND patients and healthy control.

    Measured: 1 day

  6. Electrophysiological measure (EEG): Heartbeat evoked potential (HEP) task2

    First, study the difference of mismatch negativity (MMN) evoked potential either if external tone was synchronous or asynchronous with heartbeat. Then comparison between FND patients and healthy control.

    Measured: 1 day

  7. Neurophysiological measures: Correlation between agency task and respiration cycle (Libet)

    Study of the correlation between a free will key press and the state in respiration cycle. Then comparison of the results between FND patients and healthy control.

    Measured: 1 day

  8. Electrophysiological measure (EEG): the readiness potential (Libet)

    Analysing the readiness potential related with the motor movement in the implicit compared to the explicit trigger. Then comparison of the results between FND patients and healthy control.

    Measured: 1 day

  9. The localization of neuronal activity derived from EEG during interoceptive tasks, and during resting state

    Use of the EEG signal during cardiac interception task (HEP),agency task (Libet) and resting to estimate the source generator of brain activities (inverse solution).

    Measured: 1 day

  10. Behavioral measure: Correlation between oxytocin and clinical questionaire

    Correlating the scores or categories of childhood trauma, attachment style and sexual functioning to oxytocin levels.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2023
  2. Study start5 Oct 2023
  3. Primary completion24 Jan 2025
  4. Study completion24 Jan 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06084325
Sponsor's protocol ID
2023-00469
Other IDs
2023
Status last verified
Mar 2025
First submitted
20 Sep 2023
Last updated
27 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Functional Neurological Disorder, run by University of Fribourg at 2 sites in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference of interoception behavioural scores between FND patients and Healthy controls (time frame: 1 day). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in